These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9733334)

  • 1. The economic consequences of Alzheimer's disease in the context of new drug developments.
    Knapp M; Wilkinson D; Wigglesworth R
    Int J Geriatr Psychiatry; 1998 Aug; 13(8):531-43. PubMed ID: 9733334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
    Lamb HM; Goa KL
    Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
    Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.
    Wimo A
    Drugs Aging; 2004; 21(5):279-95. PubMed ID: 15040756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Mauskopf JA
    Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.
    McNamee P; Vanoli A; Hutchings D; McKeith I; Bond J
    J Nutr Health Aging; 2010 Oct; 14(8):664-8. PubMed ID: 20922343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2002; 20(13):919-42. PubMed ID: 12381243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
    Courtney C; Farrell D; Gray R; Hills R; Lynch L; Sellwood E; Edwards S; Hardyman W; Raftery J; Crome P; Lendon C; Shaw H; Bentham P;
    Lancet; 2004 Jun; 363(9427):2105-15. PubMed ID: 15220031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Bosanquet N; Yeates A
    Pharmacoeconomics; 2006; 24(6):623-5; author reply 625-6. PubMed ID: 16761908
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
    Versijpt J
    Acta Neurol Belg; 2012 Jun; 112(2):141-5. PubMed ID: 22476975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological therapy for people with Alzheimer's disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs.
    Ballard C; Sorensen S; Sharp S
    J Alzheimers Dis; 2007 Aug; 12(1):53-9. PubMed ID: 17851194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic effect of cholinesterase inhibitor therapy: implications for managed care.
    Sano M
    Manag Care Interface; 2004 Aug; 17(8):44-9. PubMed ID: 15471110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
    Winblad B; Brodaty H; Gauthier S; Morris JC; Orgogozo JM; Rockwood K; Schneider L; Takeda M; Tariot P; Wilkinson D
    Int J Geriatr Psychiatry; 2001 Jul; 16(7):653-66. PubMed ID: 11466744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based pharmacotherapy of Alzheimer's disease.
    Evans JG; Wilcock G; Birks J
    Int J Neuropsychopharmacol; 2004 Sep; 7(3):351-69. PubMed ID: 15228642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
    Versijpt J
    J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.
    Jönsson L
    Pharmacoeconomics; 2003; 21(14):1025-37. PubMed ID: 13129415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
    Ward A; Caro JJ; Getsios D; Ishak K; O'Brien J; Bullock R;
    Int J Geriatr Psychiatry; 2003 Aug; 18(8):740-7. PubMed ID: 12891643
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.